Zika without symptoms in returning travellers : What are the implications? by Ginier, Mylène et al.
1 
 
Zika without symptoms in returning travellers, what are 
the implications 
 
Mylène Ginier1,2, Andreas Neumayr2,3*, Stephan Günther4,5, Jonas Schmidt-Chanasit4,5, 
Johannes Blum2,3 
 
1.  University of Lausanne, Switzerland 
2.  Swiss Tropical and Public Health Institute, Basel, Switzerland 
3.  University of Basel, Switzerland 
4.  WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research, Bernhard-Nocht 
Institute for Tropical Medicine, Hamburg, Germany 
5. German Centre for Infection Research (DZIF), partner site Hamburg-Luebeck-Borstel, Hamburg, Germany 
* corresponding author: Email: andreas.neumayr@unibas.ch; Tel.: +41 61 284 8255; Fax: +41 61 284 8183 
 
Abstract 
Against the background of the emergence and rapid spread of Zika virus (ZIKV) in the 
Americas we report the case of an afebrile ZIKV infection in a traveller returning from Central 
America to exemplarily highlight relevant clinical and diagnostic aspects. ZIKV should be 
considered in the differential diagnosis of patients with clinical symptoms suggestive of 
dengue or chikungunya fever. Regarding the frequent subfebril and afebrile manifestation of 
ZIKV infections we propose to abstain from the term "Zika fever (ZF)" in favor of "Zika virus 
disease (ZVD)". Owing to its unspecific clinical presentation and cross-reactivity in 
serological assays, ZVD may easily be missed or misdiagnosed as dengue fever. Until 
conclusive data on the currently suspected link between ZIKV infection in pregnancy and 
foetal microcephaly become available, pregnant women and women who are trying to 
become pregnant should be advised against travelling to regions with ongoing ZIKV 
transmission. In addition, male travellers returning from regions with ongoing transmission 
should be informed on the potential risk of sexual transmission until conclusive data on the 
significance of this mode of transmission become available. Although probably low and 
seasonally restricted, there is a risk of ZIKV importation to Aedes mosquito infested regions 
in temperate climates (including regions of North America and Europe) with consecutive 
autochthonous transmission. 
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Background 
Like DENV, yellow fever virus, West Nile virus and Japanese encephalitis virus, ZIKV is a 
medical important mosquito-transmitted virus belonging to the flavivirus family. Similar to 
other flavivirus infections, asymptomatic infections are common with only one in five infected 
individuals developing unspecific symptoms (mild fever, rash, conjunctivitis, and arthralgia) 
and the clinical presentation may easily be confused with other viral infections, especially 
with DENV and CHIKV [1]. Since the virus’s discovery in a sentinel Rhesus monkey in the 
Zika forest in Uganda in 1947, human infections have only sporadically been reported in Asia 
and Africa. In 2007, ZIKV emerged outside its known endemic boundaries for the first time 
and caused an epidemic on Yap Island in the Federated States of Micronesia [1], followed by 
a large epidemic in French Polynesia in 2013–14 [2] and subsequent spread to several 
countries in Oceania, including New Caledonia and the Cook Islands [3]. While ZIKV was 
generally considered to only cause mild human disease, the outbreak in French Polynesia 
revealed the virus’s potential to cause neurological complications (i.e. Guillain-Barré 
syndrome and meningoencephalitis)[4]. 
On May 7, 2015, the Pan American Health Organization issued an alert about potential ZIKV 
transmission in northeastern Brazil [5]. Following this first detection of ZIKV on the American 
continent, autochthonous ZIKV transmission has rapidly been confirmed throughout Central 
and South America (Figure 2). The number of cases observed in Brazil alone was estimated 
at 440’000–1’300’000 [6]. Closely following the emergence and rapid spread of CHIKV in the 
Americas since 2013 [7, 8], ZIKV is now the second arbovirus emerging on the American 
continent in recent years. As ZIKV shares the Aedes mosquito vector with DENV and CHIKV, 
and half of the world’s population is living in Aedes-infested regions, the possibility of ZIKV 
epidemics are a major public health concern [9]. On top, data suggest that ZIKV may be 
sexually [10] as well as transplacental transmissible [11, 12]. Especially the latter is currently 
raising concerns, after in October 2015, the Brazilian ministry of health reported a twentyfold 
increase in the number of microcephaly cases among newborns compared with previous 
years [12]. Although maternal-foetal transmission of ZIKV has been documented throughout 
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pregnancy and the detection of ZIKV RNA in pathologic specimens of foetal losses as well as 
confirmed ZIKV infections in infants with microcephaly suggest a link between ZIKV infection 
in pregnancy and microcephaly of the foetus, the incidence of ZIKV infection in pregnant 
women is currently not known and the definitive proof of a causal link is still pending [13]. 
 
Case description 
A 51-year-old female Swiss traveller presented to our outpatient department six days after 
returning from a two-week holiday to Guatemala and El Salvador in November 2015. Four 
days after returning, the patient noticed a slightly pruritic maculopapular rash on the face, 
trunk, and extremities without accompanying symptoms (neither fever nor symptoms 
suggestive of a systemic infection). On the next day the rash worsened and a non-purulent 
conjunctivitis developed. We saw the patient another day later when additionally painful 
oedemas of the hands, elbows, knees and feet (Figure 1) had developed. Besides the rash, 
the conjunctivitis, the oedemas and a generalized lymphadenopathy the physical 
examination was unremarkable. The performed laboratory tests included complete blood 
count, hepatic transaminases, creatinine, C-reactive protein and rapid tests for dengue virus 
(DENV) (NS1-Ag, IgM, IgG [SD Dengue Duo; Standard Diagnostics Inc., Korea]) and 
chikungunya virus (CHIKV) (IgM [Nadal Chikungunya IgM Combo; Nal von Minden GmbH, 
Germany]). Besides an elevated C-reactive protein (8mg/l [reference <5]) and a raised 
creatinine (87µmol/l [reference range 35–80]) all laboratory parameters were unremarkable 
and the rapid tests for DENV and CHIKV indicated no acute or past infection. On follow-up 
six days later, the conjunctivitis and oedemas had completely resolved and the rash was 
fading (finally disappearing two days later) while the patient was complaining about fatigue. 
As the suspicion of a viral infection remained high, we repeated testing for DENV and CHIKV 
infection with the above mentioned rapid tests and demonstrated seroconversion for anti-
DENV IgG while anti-DENV IgM remained negative. Due to the well know serological cross-
reactivity among flaviviruses we considered a Zika virus (ZIKV) infection of the patient and 
sent both sera to the WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever 
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Reference and Research at the Bernhard-Nocht-Institute, Hamburg, Germany were the sera 
were tested for DENV, CHIKV and ZIKV, respectively (Table 1). Our suspicion of a ZIKV 
infection was confirmed by real-time RT-PCR (RealStar® Zika Virus RT-PCR Kit 1.0, altona 
diagnostics, Hamburg, Germany) and serology. Two weeks after the onset of symptoms the 
patient had fully recovered. 
 
Discussion 
As clinical symptoms of Zika fever (ZF) may easily be confused with dengue fever (DF), it 
deserves to be highlighted that unlike in DF, fever is more sporadic and frequently milder in 
ZIKV infections [1]. In our patient ZF only manifested with skin rash and peripheral oedema 
while neither fever nor general symptoms were noted. Similar afebrile and subfebrile 
manifestations of ZF have repeatedly been reported in the past, including e.g. two cases 
imported from French Polynesia to Japan [14] and, more recently, the case of a Dutch 
traveller returning from Surinam who presented with a maculopapular rash on the trunk and 
extremities, skin hypersensitivity, and arthralgia only [15]. Therefore, the absence or only 
mild manifestation of fever and general symptoms in a patient presenting with symptoms 
suggestive of DF (i.e. headache, rash, conjunctivitis, musculoskeletal complaints) should 
raise the suspicion of a ZIKV infection and we propose to abstain from the term "Zika fever 
(ZF)" in favor of "Zika virus disease (ZVD)". 
As ZIKV and DENV are both flaviviruses, cross-reactivity in serological assays may lead to 
confusion and misdiagnosis. While DENV NS1-antigen tests are mostly specific for DENV, 
serological assays detecting anti-DENV-IgM and anti-DENV-IgG may show cross-reactivity. 
The diagnostic value of RT-PCR for detection of ZIKV RNA in blood is limited as viremia is 
usually low and limited to the first 2–3 days after disease onset (which is often not 
determinable as fever and general symptoms may be mild or absent)[16]. However, ZIKV 
RNA detection in urine provides a feasible alternative: ZIKV is detectable with higher RNA 
loads and for a longer period (10–20 days after onset of symptoms) in urine samples than in 
serum samples [16]. 
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Regarding the suspected link between ZIKV infection during pregnancy and foetal 
microcephaly, many questions remain to be answered, e.g. it is currently unclear whether 
additional factors may be involved and whether the risk of microcephaly may depend on the 
time point of infection during pregnancy. Since the ZIKV epidemic in the Americas is rapidly 
emerging and a potential link between ZIKV infection during pregnancy and microcephaly of 
the foetus appears plausible, the US and the European Centres for Disease Control and 
Prevention advice pregnant women and women who are trying to become pregnant against 
travelling to regions where ZIKV transmission is ongoing [13, 17]. In addition, a testing 
algorithm for pregnant women returning from an area with ongoing ZIKV transmission has 
been published [13]. An issue not yet addressed by the health authorities is the prolonged 
detection of ZIKV in semen and the documented transmission of ZIKV by sexual intercourse 
[9, 18] which may have implications in male travellers return from regions with ongoing 
transmission. Considering that asymptomatic infections are frequent, it should be considered 
to advice male travellers on the use of condoms after returning from regions with ongoing 
transmission until conclusive data on the significance of this mode of transmission become 
available. 
Although the viremia in ZVD is apparently much lower and the viremic phase shorter than in 
DF and chikungunya fever (CF), international travellers pose a risk for the intra- and 
intercontinental spread of ZIKV [19]. The risk of ZIKV importation and consecutive 
autochthonous transmission also includes non-tropical areas like the Aedes aegypti and A. 
albopictus infested regions of the United States and the A. albopictus infested regions of 
Southern Europe. Reports of importation and autochthonous transmission of DENV and 
CHIKV in Florida and Southern Europe in recent years support this assumption [20–27]. The 
risk of introduction and autochthonous transmission depends on the regional prevalence and 
seasonal population density of suitable mosquito vectors. For example, entomological 
monitoring in the Mediterranean region indicates that the development period for A. 
albopictus starts in April and tapers off in October/November with activity peaks in June/July–
September [28–30]. Not surprisingly, the cases of autochthonous DENV and CHIKV 
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transmissions in Southern Europe in recent years were all reported between August and 
October [20–27]. Therefore, unlike in tropical and subtropical regions, the autochthonous 
transmission risk in regions with temperate climate is seasonally restricted [19]. 
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Table 1. Virological tests performed with samples from the Zika virus infected patient. 
   
 First serum sample† Second serum sample‡ 
   
   
Dengue IgM IIFT negative negative 
Dengue IgG IIFT 1:20 1:5120 
Dengue NS1-Ag negative negative 
Zika IgM IIFT negative 1:640 
Zika IgG IIFT 1:20 1:5120 
Zika qRT-PCR positive ND 
Chikungunya IgM ELISA negative ND 
Chikungunya IgM IIFT ND negative 
Chikungunya IgG IIFT ND negative 
   
 
†  sample obtained 6 days after onset of symptoms 
‡  sample obtained 7 days after the first serum sample 
IIFT: Indirect Immunofluorescence Test; qRT-PCR: real-time reverse transcription polymerase chain 
reaction; ELISA: Enzyme-linked Immunosorbent Assay; ND: not done. 
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Figure 1. Clinical features of Zika virus disease: (A) conjunctivitis, (B) maculopapular 
rash, (C-D) peripheral oedemas. 
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Figure 2. Reported active autochthonous Zika virus transmission in the Americas as of 
January 26, 2016. 
  
